# EsbaTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/esbatech

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.esbatech.com
- Total disclosed funding: $69M
- Latest round: Series B (Aug 7, 2008)
- Investors on record: 8

## About

EsbaTech specializes in providing innovative technology solutions that enhance operational efficiency for mid to large-sized enterprises across various sectors, including finance, healthcare, and logistics.EsbaTech, founded in 1998 in Zurich, Switzerland, develops advanced software platforms aimed at streamlining data management and analytics for businesses. The company was acquired by Alcon in September 2009. It has completed a total of 4 deals, with its latest round of funding being a Series B that raised USD 22.00 mn, involving investors like BioMed Partners and Novartis Venture Fund.EsbaTech.com offers a range of innovative technology solutions focused on enhancing operational efficiency. The company's primary offerings include advanced software platforms that support data management, analytics, and integration, aimed at optimizing workflows and resource allocation for mid to large-sized enterprises in sectors like finance, healthcare, and logistics. Their products facilitate data-driven decision-making and are marketed across North America, Europe, and select Asian markets.EsbaTech.com generates revenue through a subscription-based model, allowing clients to access their software solutions on a recurring basis. Each subscription plan is customized to meet specific business needs, with different tiers providing varying levels of functionality and support. Their flagship product, recognized for its robust analytics capabilities, is offered through multiple pricing plans based on deployment complexity. This model fosters predictable cash flow through annual or monthly billing cycles.EsbaTech is focused on expanding its product offerings and geographical reach. The company plans to launch new products aimed at enhancing data integration capabilities, with specific release dates to be announced. Additionally, EsbaTech targets expansion into emerging markets in Asia and South America by 2022. The recent funding from the Series B round of USD 22.00 mn will be utilized to support these initiatives, enhancing their technological infrastructure and marketing efforts.

## Funding rounds

- Series B, Aug 7, 2008, $22M — HBM Partners, Novartis Venture Fund, BioMed Partners, SV Health Investors, Clarus Ventures, Vi Partners
- Series B, Aug 2, 2006, $41M — HBM Partners, Novartis Venture Fund, BioMed Partners, SV Health Investors, Clarus Ventures, Vi Partners
- Series B, May 14, 2002, $6.2M — HBM Partners, Novartis Venture Fund, BSI Group, Lombard Odier Darier Hentsch (Asia)

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- BSI Group — Series B
- Lombard Odier Darier Hentsch (Asia) — Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B
- Clarus Ventures (https://capitalatlas.ai/funds/clarus-ventures) — Series B
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series B